Appendix P. Aj

CC CC iden		SQ Seq Query Best L	Macche Oy	8 8 8	8 8 1	g &	q _O
541 AGCCATGTGATCCTACACACACACACACACAGGCCGTGGGCGAAGCTGGCCTGTGGA 600	661 TIGITITGCATIGGTCICCTANGCCCTAATIGCACAAGCTGTCCTTCGCCTCTCATCC 720	721 CATGAAGCTCGGTCCAAGGCCTTAGGACCTGGGTTCCCATGTCTGTGATCATCTCT 780	781 TCTTATACACCAGCCCTCTTCTCCTTTTTACACACCGCTTTGGCCATCACGTTCCAGGTC 840	841 CATATTCACATTCTTTGGCCAATGTTTATCTGCTTTTGCCACCTGCTCTTAATCCTGTG 900	901 GIATALGGAGTIAAGACCAAACAGATCCGTAAAAGAGTTGTCAGGGGTGTTTCAAGGTGGG 960 	961 CAGGGAATGGCCATCAAGGCATCTGAG 987 	
		- ^	~ n	> A	Ş; q	% 43	

AAH31850 standard; DNA; 963 AAH31850; AMH31850

AMC
 AAH3

AMC
 AMC
 AAH3

(first entry) 30-JUL-2001

Human olfactory receptor polynucleotide, SEQ ID NO: 423.

Human, olfactory receptor, OR; primary scent determination, secondary scent determination; polypeptide library; odour receptor; scent profile; scent fingerprint; scent representation; ds.

WO200127158-A2

19-APR-2001

06-OCT-2000; 2000WO-US027582

08-OCT-1999; 99US-0158615P. 24-FEB-2000; 2000US-0184809P.

(DIGI-) DIGISCENTS. (YEDA) YEDA RES & DEV CO LID.

e, à WPI; 2001-290713/30.

Fuchs

ϋ

Glusman

Lancet

Bellenson J, Smith D,

New polynucleotides which encode polypeptides involved in olfactory sensation for identifying olfactory agonists and antagonists. Claim 8; Page 349; 1857pp; English

The present sequence is one of a number of isolated polynucleotides which encode polypeptides involved in olfactory sensation. The polynucleotides

an be used in screening for olfactory agonists and antagonists. The ethods allow for the determination of primary scents and the dentification of the odour receptors used to detect these primary cents. The methods also enable determination of secondary scents and the fartification of combinations of odour receptors that are involved in execting such secondary scents. This enables the construction of a scent spreamation (also called a scent fingerprint or scent profile), which ay be used to re-create and edit scents. Libraries of olfactory seceptors are useful for determining the interaction pattern of a supposition with the receptors, and can be used for determining the liferences in the olfactory faculties of different individuals ò 240 GCCTTTGATCGCTACGTGGCCATCTGCCACTCCGCTATGCCACATCCTCACTGAC 444 120 180 264 324 GCACAGAGATGTTCTTCATGCATGCTTCTGCATGATGGAGTCCACGTGCTACTGGCCATG 360 504 564 624 009 625 GGGCTGACACTGCACTGTTGGTCATTGGGGTTGATTTGTTTTGCATTGGTCTCTAT 684 099 744 804 780 204 GCACATATGTTCTTCATTCATGCCTTCTGCATGATGGAGTCCACTGTGCTACTGGCCATG 384 TTTTTACACACCGCTTTGGCCATCACGTTCCAGTCCATATTCACATTCTTTTGGCCAAT 864 1 AIGGAAICTCCTPAICACACTGAIGTIGACCTITCTCTTCTTCTTCTCTCTGGGCAICCCA 60 GGGCTGACAGCTGCACTGTTGGTCATTGGGGTTGACTTGTTTTGCATTGGTCTCTCCTAT 25 AIGGAAICTCCICATCACACIGAIGITGACCCITCTGTCTTCTTCCTCCTGGGCAICCCA 145 ATTGTGGGCAATATAACTATTCTGGTTGTTGCCACTGAACCAGTCTTGCACAAGCCT GIGIACCTITITICIGICALGCICICAACCAICGACTIGGCIGCCICTGICTCCACAGIT GIGHTHILLING 445 ACCATCATTGCCCACATAGGGTGGCTGTAGTGCGAGGCTCCCTGCTCATGCTCCCA TGTCCCTTCTTTATTGGGCGTTTGAACTTCTGCCAAAGCCATGTGATCCTACACGTAC TGTGAGCACATGGCTGTGGTGAAGCTGGCCTGTGGAGACACCAGCCTAACCGTGTGTAT GCCCTAATTGCACAAGCTGTCCTTCGCCTCTCATCAAGCTCGGTCCAAGGCCCTA GGGACCTGTGGTTCCCATGTCTGTGTCTCTTCTTTATACACCAGCCCTCTTCTCC GGGACCIGIGGTTCCCATGTCTGTGTCTCATCTTTATACACCAGCCCTTTCTCC 0 Match
Local Similarity 99.6%; Pred. No. 4.1e-300;
es 959; Conservative 0; Mismatches 4; Indels 0 quence 963 BP; 181 A; 276 C; 216 G; 290 T; 0 U; 0 Other; 505 565 61 205 265 325 385 421 601 685 661 745 802 781 181 301 721 g à δ d ò D ò 셤 à g ò 엄 ò g $\dot{\delta}$. d ठे g

Mon Aug

Roberton 192

The invention relates to a novel human G-coupled receptor (1). (1) and its corresponding polynuclectides are useful for diagnosing, treating or preventing cell proliferative diseases (e.g. lymphoma, leukaemia, breast cancer or cirrhosis), neurological disorders (e.g. troke, Alzheimer's disease, multiple sclerosis or mental retardation), cardiovascular diseases (e.g. atherosclerosis, angina pectoris or congestive heart failure), gastrointestinal disorders (e.g. dysphagia, indigestion or gastritis), autoimmune/inflammatory disorders (e.g. AIDS, Crohn's disease or systemic lupus erythematosus) or metabolic disorders (e.g. diabetes or New G-protein coupled receptors useful for treating or preventing cell proliferative (e.g. leukemia), neurological (e.g. stroke), cardiovascular or autoimmune/inflammatory disorders. 924 900 984 960 Human; cytostatic; neuroprotective; immunosuppressant; nootropic; anti-inflammatory; anti-viral; gastrointestinal; cardiovascular; cerebroprotective; G-coupled receptor; cell proliferative disease; lymphoma; leukaemia; breast cancer; cirrhosis; neurological disorder; stroke; Alzheimer's disease; multiple sclerosis; mental retardation; cardiovascular disease; autherosclerosis; angina pectoris; indigestion; congestive heart failure; gastrointestinal disorder; dysphagia; AlDS; gastritis; autoimmune disorder; inflammatory disorder; Crohn's disease; systematic lupus arythematosus; metabolic disorder; diabetes; obesity; acquired immune deficiency syndrome; ss. 841 GITTATCIGCITITGCCACCIGCICITAATCCIGIGGIATAIGGAGITAAGACCAAACAG ATCCGTAAAAAGGGGTGTTCAAAGTGGGCAGGGAATGGGCATCAAGGCATCT × ដ Thornton M, Human G-coupled receptor (GCREC) cDNA, Seg ID No 42. Griffin JA, ZM, Yao MG, Au-Young J; 5; Page 146; 148pp; English ABK16633 standard; cDNA; 966 BP. 25-MAY-2000; 2000US-0207476P. 02-JUN-2000; 2000US-0208834P. 02-JUN-2000; 2000US-0208861P. 22-MAY-2001; 2001WO-US016833 2000US-0209868P CM, (INCY-) INCYTE GENOMICS INC Tribouley Gandhi AR, WPI; 2002-106199/14. P-PSDB; AAU80511. GAG 987 GAG 963 WO200190359-A2 07-JUN-2000; 22-MAY-2000; Patterson C, Kallick DA, Homo sapiens 925 901 985 961 Claim ABKULT 9
ABKULT 9
ABKULT 9
ABKULT ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABKULT
ABK 엄 a à 셤 ò

ö 120 204 180 264 240 384 360 444 420 504 480 564 540 624 900 684 099 744 804 960 144 324 661 GCCCTAAGTGCACAAGCTGTCCTTCGCCTCTAATCCCATGAAGCTCGGTCCAAGGCCCTA 720 780 900 864 924 84 9 301 GCACAGATGTTCTTCATTCATGCCTTCTGCATGATGGAGTCCACTGTGCTACTGGCCATG 181 GIGIACCITITICIGIGIAN PROPERTING CITICAL CALCAGIT GCACATATGTTCTTCATTCATGCCTTCTGCATGATGGAGTCCACTGTGCTACTGGCCATG 505 IGTCCCTTCTTTATTGGGCGTTTGAACTTCTGCCAAAGCCATGTGATCCTACACACGTAC 901 ATCCGTAAAAAAGGGTGTTTCAAAGTGGGCAGGGAATGGGCATCAAGGCATCT GCCTTTGATCGCTACGTGCCATCTGCCACCCCACTCCGCTATGCCACAATCCTCACTGAC 361 GCCTTTGATCGCTACGTGGCCATCTGCCACTCCGCTATGCCCACAATCCTCACTGAC 445 ACCATCATTGCCCACATAGGGGTGGCAGCTGTAGTGCGAGGCTCCCTGCTCATGCTCCCA 541 IGTGAGCACATGGCTGTGAAGCTGGCCTGTGGAAGACACCAGGCCTAACGTGTAT GGGCTGACAGCTGCACTGGTCATTGGGTTGACTTGTTTTGCATTGGTCTCTCTAT 601 GGGCTGACAGCTGCACTGTTGGTCATTGGGGTTGACTTGTTTTTGCATTGGTCTCTCTAT 841 GTTTATCTGCTTTTTGCCACCTGCTCTTAATCCTGTGGTATATGGAGTTAAGACCAAACAG 1 AIGGAAICTCCIAAICACACTGAIGITGACCCTICTGTCTICTTCCTCCTGGGGAICTCCA GGICTGGAACAATTICAITIGIGGCTCTCACTCCCTGIGIGIGGCTTAGGCACAGCCACA 121 ATTGTGGGCAATATAACTATTCTGGTTGTTGCCCACTGAACCAGTCTTGCACAAGCCT TGTGAGCACATGGCTGTGAAGCTGGCCTGTGGAGACACCAGGCCTAACCGTGTAT 721 GGGACCTGTGGTTCCCATGTCTGTGTCTCTTTTATACACCAGCCCTTTTCTCC 25 ATGGAATCTCCTCATCACACTGATGTTGACCCTTCTGTCTTCTTCCTCCTGGGCATCCCA 145 ATTGTGGGCAATATAACTATTCTGGTTGTTGTTGCCACTGAACCAGTCTTGCACAAGCCT GTGTACCTTTTTCTGTGCATGCTCTCAACCATCGACTTGGCTGCCTCTGTCTCCACACTT GCCCTAATTGCACAAGCTGTCCTTCGCCTCTCATCCCATGAAGCTCGGTCCAAGGCCCTA GGGACCTGTGGTTCCCATGTCTGTGTCATCCTCATCTCTTATACACCAGCCCTCTTCTCC 781 TITITIACACACCGCTTTGGCCATCACGTTCCAGTCCATATTCACATTCTTTGGCCAAT GTTTAICTGCTTTTGCCACCTGCTCTTAATCCTGTGGTATATGGAGTTAAGACCAAACAG 925 ATCCGTAAAAGAGTTGTCAGGGTGTTTCAAAGTGGGCAGGGAATGGGCATCAAGGCATCT Gaps obesity), or viral infections (e.g. infection by herpesvirus or parvovirus). ABK16615-ABK16637 represent novel human G-coupled coding sequences of the invention 0; Length 966; Sequence 966 BP; 182 A; 276 C; 217 G; 291 T; 0 U; 0 Other; Indels Score 956.6; DB 6; Pred. No. 4.1e-300; 96.9%; Scor. 99.6%; Pred. No. *... al Similarity 99.6 959; Conservative 565 385 85 625 685 745 805 865 205 265 325 Query Match Matches 8 x 8 8 8 8 g g 쉼 d g a g ð 셤 g g 셤 g à ઠે 셤 à ò ò ð ò ð ò 셤 ò 쉼 ò a ð à à

Appen out AS

985 GAG 987 ò g

961 GAG 963

RESULT 10 ABK68612

ABK68612;

ABK68612 standard; DNA; 966 BP.

(first entry) 02-JUL-2002 Human DNA for olfactory and pheromone G protein-coupled receptor #212.

Human; ds; gene; olfactory and pheromone G protein coupled receptor; GPCR; tranquilizer; antidepressant; neuroleptic; endocrine; anabolic; anorectic; taste; fragrance; food additive; cosmetic; cell migration; sterility; psychotic disorder; neurological disorder; anxiety; schizophrenia; manic depression; depression; axonal growth; menstrual cycle; appetite sexual motivation; sexual attraction; aggression.

Homo sapiens

WO200224726-A2.

28-MAR-2002.

21-SEP-2001; 2001WO-BE000162.

22-SEP-2000; 2000EP-00870211

(CHEM-) CHEMCOM SA

Veithen A;

WPI; 2002-330013/36. P-PSDB; AAU95725.

Novel pheromone G-protein coupled receptor and receptor-derived agonists, antagonists or inhibitors useful in food or cosmetic products or in the treatment or prevention of neurological disorders such as anxiety and schizophrenia.

Disclosure; Page 646-647; 833pp; English

The invention relates to olfactory and Pheromone G-protein coupled
receptor (GPCR) or a protein 95% identical to the GPCR, a specific active
portion and itse encoding polynucleotide. Also included are an agonist,
antagonist or inhibitor of the GPCR or the polynucleotide, a vector
comprising the polynucleotide, a cell transformed by the vector, a nonhuman mammal-comprising a partial or total deletion of the polynucleotide
compounds which are known or not known to be agonist, antagonists or
compounds which are known or not known to be agonist, antagonists or
inhibitors of natural compounds to the GPCR. The receptor-derived
compounds which are subscitction of an existing taste and/or a improvement, elimination or subscitction of an existing taste and/or a fragrance of (or in) the food and/or cosmetic products. They can also be
consection the preparation of medicament in the treatment and/or prevention
of a mammalaian disorders, such as cell migration, sterility, psychotic and
neurological disorders, including anxiety, schizophrenia, manic
connection and nerve regeneration for modulating male and female
connections, hormone production and the menstrual cycle, for the
prevention or the treatment by stimulation of several mammalian
concerning chunctions, hormone production and the menstrual cycle, for prevention, sexual attraction, aggression and for promoting or
suppressing chemical communication between organisms. The present
consequence is a human DNA encoding an olfactory and pheromone GPCR

Sequence 966 BP; 182 A; 276 C; 217 G; 291 T; 0 U; 0 Other;

961 GAG 963

셤

Query Matc Best Local Matches	th 96.9%; Score 956.6; DB 6; Length 966; Similarity 99.6%; Pred. No. 4.1e-300; Conservative 0; Mismatches 4; Indels 0; Gaps
Š	
ą	rógaarcrectaareacacreargresecerrerererecreceregegarres
<u>ک</u> د	85 GGTCTGGAACAATTTCATTTGTGGCTCTCACTCCTGTGTGGGCTTAGGCACAGCCACA 144 61 GTTTTGAACAATTTCATTTGTGGCTCTCACTGTGTGTGGCTTAGGCACACAA 120 61 GGTCTGAACAATTTCATTTGTTAGGCTTGTGTGTGTGTGT
3 8	5 ATTGTGGGCAATATAACTATTCTGGTTGTTGTTGCCACTGAACCAGTCTTGCACAAGCCT 20
: 원	21 ATTGTGGGCAATATAAACTATTCTGGTTGTTGTTGCCACTGAACCAGTCT
ζ	56
Op	TTTTTCTGTGCATGCTCTCACATCGACTTGGCTGCCTCTG
දු ද	265 CCCAAGCTACTGGCTATCTTCTGGTGTGGAGCCGGACATATATCTGCCTCTGCCTGC
3 8	18 と、 かいましていかから 18 12 12 12 12 12 12 12 12 12 12 12 12 12
5 A	01 GCACAGATGTTCTTCATTCATGCCTTCTGCATGATGGAGTCCACTGTGCTACTGGCCATG
ζ	CCTTTGATCGCTACGTGGCCATCTGCCCACCCACTCCGGCTATGCCACACACTCCTCACTGA
οgo	361 GCCTTTGATCGCTACGTGGCCATCTGCCACTCCGCTATGCCACATCCTCACTGAC 420
ζŏ	445 ACCATCATTGCCCACATAGGGGTGGCAGCTGTAGTGCGAGGCTCCCTGCTCATGCTCCCA 504
Ор	ATCATTGCCCACATAGGGGTGGCTGCTAGTGCGAGGCTCCCTGCTCATGCTCCCA 48
ò	505 TGTCCCTTCTTTATTGGGCGTTTGAACTTCTGCCAAAGCCATGTGATCCTACACACGTAC 564
q _O	54
δ	565 TGTGAGCACATGGCTGTGAGGTGGCTGTGGAGACACCAGGCCTAACCGTGTGTAT 624
QQ	9
ζō	625 GGGCTGACAGCTGCACTGTTGGGGTTGACTTGTTTTTGCALTGGTCTCTCTAT 684
QQ	601 GGGCTGACAGCTGCTGCTTTGGCTTTGACTTGTTTTTGCATTGGTCTCTCCTAT 660
δλ	
Db	CCCTAAGTGCACAAGCTGTCTTCGCCTCTCATGCAAGCTCGGTCCAAGGCCCTA 72
δλ	745 GGGACCTGTGGTTCCCATGTCTGTGTCATCCTCATATACACCAGCCTCTTCTCC 804
QQ	cranagricccaraterarcarecrearcrearateaecaaecererrer
δλ	805 TITHITACACCGCTITGGCCATCACGTTCCAGACATATATACACATTCTTTTGCCCAAT 864
Ωþ	CGCTTTGGCCATCACGTTCCAGTCCATATT
ζō	865 GITIAICHGCITITIGCCACCIGCICITIAAICCIGIBGIAIAAGGAGTIAAGACCAAACAG 924
ΩÞ	TGCTTTTGCCACCTGCTCTTAATCCTGTGGTATATGGAGTTAAGA
λ̈́o	25 ATCCGTAAAAGAGTTGTCAGGGTGTTTCAAAGTGGGCAGGGAATGGGGCATCAAGGCATCT 98
අූ	CCGTAAAAGAGTTGTCAGGGTGTTTCAAAGTGGGGCAGGGAATGGGCATCAAGGCAT
λŏ	985 GAG 987